Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody in...
Sunshine Guojian Pharmaceutical (Shanghai) reported revenue of 4.20 billion CNY for fiscal year 2025, up 251.8% from fiscal year 2024, and net income of 2.90 billion CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 431.23 million CNY, up 38.6% from a year before. Other Countries and Regions was its largest region in fiscal year 2025, with 68% of revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.